| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/10428194.2016.1153087 |
| P698 | PubMed publication ID | 26917050 |
| P50 | author | Kiyomi Mashima | Q61187428 |
| P2093 | author name string | Takahiro Suzuki | |
| Hirofumi Nakano | |||
| Kazuya Sato | |||
| Kazuo Muroi | |||
| Chihiro Yamamoto | |||
| Daisuke Minakata | |||
| Iekuni Oh | |||
| Kaoru Hatano | |||
| Ken Ohmine | |||
| Kento Umino | |||
| Kiyoshi Okazuka | |||
| Miyuki Sugimoto | |||
| Ryoko Yamasaki | |||
| Shin-Ichiro Fujiwara | |||
| Yasufumi Kawasaki | |||
| Yoshinobu Kanda | |||
| Masahiro Ashizawa | |||
| Shoko Ito | |||
| P2860 | cites work | CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | Q29620607 |
| Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) | Q33758413 | ||
| Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | Q34042800 | ||
| The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature | Q35103330 | ||
| The myth of the second remission of acute leukemia in the adult | Q36619678 | ||
| The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients | Q36832124 | ||
| Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. | Q37792960 | ||
| Management of refractory acute myeloid leukemia: re-induction therapy or straight to transplantation? | Q37943251 | ||
| The role of decitabine for the treatment of acute myeloid leukemia | Q38056891 | ||
| Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party | Q38434694 | ||
| A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. | Q39937037 | ||
| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | Q40186710 | ||
| Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation | Q40633997 | ||
| Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia | Q40746796 | ||
| Investigation of the freely available easy-to-use software 'EZR' for medical statistics | Q41513106 | ||
| Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia | Q44468873 | ||
| Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). | Q45997441 | ||
| Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. | Q46170697 | ||
| Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis | Q58023968 | ||
| P433 | issue | 11 | |
| P921 | main subject | cytarabine | Q180983 |
| etoposide | Q418817 | ||
| P304 | page(s) | 2541-2547 | |
| P577 | publication date | 2016-02-25 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia | |
| P478 | volume | 57 |
Search more.